Medigus’ Polyrizon Inks Agreement To Develop Therapies For Traumatic Spinal Cord Injuries
Polyrizon Ltd, in which Medigus Ltd (NASDAQ:MDGS) owns a 37.03% stake, signed a binding Collaboration Agreement with NurExone Biologic Inc for therapies for traumatic spinal…
Medigus Announces Polyrizon Signs Binding Collaboration Agreement With NurExone Biologic For Intranasal Administration Of Therapy For Spinal Cord Injuries, Polyrizon Is Entitled For Up to $3.35M Plus Future Royalties; Medigus Owns 37.03% Of Polyrizon
Medigus Ltd. (NASDAQ:MDGS), a technology company engaged in advanced medical solutions, innovative internet technologies, and electric vehicle and charging solutions, announced today that Polyrizon Ltd.
Polyrizon Signed An Agreement With Nurexone For Intranasal Administration Of Therapy For Spinal Cord Injuries. BZ NOTE: Medigus Owns 37.03% Of Polyrizon
Medigus: Polyrizon Signed an Agreement with Nurexone for Intranasal Administration of Cutting - Edge Therapy for Spinal Cord Injuries
Polyrizon will be entitled for up to $3.35 million in addition to future
Medigus Announces Eventer Signs Agreements With Two Teams From The Israeli Basketball Premier League And The Israeli National Basketball League
Eventer will leverage its capabilities in the sports sector and intends to expand its outreach to leagues in the US and Europe
Tel Aviv, Israel, July 01, 2022 (GLOBE NEWSWIRE) -- Medigus Ltd. (NASDAQ:MDGS)